Skip to main content
OpenTrials

Clinical trial condition

Vascular Diseases

Explore clinical trials studying Vascular Diseases. Study availability and eligibility vary by location and protocol.

32,686 public trials 5,385 recruiting studies
Refine in advanced search Browse all conditions

Vascular Diseases trial results

Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

NCT07214324

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +19 more
Locations
  • Istituto Ortopedico Rizzoli IRCCS Bologna, Italy
  • UO Ematologia Azienda Ospedaliero-Universitaria "Policlinico Rodolico San Marco" Catania, Italy
  • UOC di Ematologia, Dipartimento di Oncologia, AOU Policlinico "Paolo Giaccone" Palermo, Italy
  • S.C Ematologia - Azienda USL IRCCS di Reggio Emilia Reggio Emilia, Italy
View Trial Details
Recruiting

Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage

NCT07338175

Conditions
Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, +10 more
Locations
  • Beijing Tiantan Hospital Beijing, Beijing Municipality, China
  • Chongqing Tongnan District People's Hospital Chongqing, Chongqing Municipality, China
  • The Second People's Hospital of Guangdong Province Guangzhou, Guangdong, China
  • Baoding Fourth Central Hospital (Tangxian, Hebei) Baoding, Hebei, China
View all 41 locations
View Trial Details
Recruiting

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

NCT06780462

Conditions
Behcet Syndrome, Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +15 more
Locations
  • CHU BORDEAUX Hôpital Saint-André Bordeaux, France
  • Ambroise Paré hospital AP-HP Boulogne-Billancourt, France
  • CHU Caen Caen, France
  • Hopital Henri Mondor AP-HP Créteil, France
View all 17 locations
View Trial Details
Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • GSK Investigational Site Mobile, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Beverly Hills, California, United States
  • GSK Investigational Site Pasadena, California, United States
View all 181 locations
View Trial Details

Related conditions